CicloMed Presents New Oncology Data from Phase I Trial with Fosciclopirox at 2020 ASCO Genitourinary Cancers Symposium
February 13, 2020 09:15 ET
|
CicloMed LLC
First-time results from recently completed fosciclopirox Phase I safety, dose tolerance, pharmacokinetics and pharmacodynamics trial in advanced solid-tumor patientsInitiation of fosciclopirox...
CicloMed Expands Fosciclopirox Phase 1 Trial to Include Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients
December 03, 2019 09:30 ET
|
CicloMed LLC
KANSAS CITY, Mo., Dec. 03, 2019 (GLOBE NEWSWIRE) -- CicloMed LLC, a biotechnology company developing novel treatments for bladder cancer, today announced the expansion of its fosciclopirox clinical...
CicloMed Announces ASCO 2018 Presentation on Clinical Trial for Ciclopirox Prodrug, Under Development for Bladder Cancer
May 31, 2018 09:30 ET
|
CicloMed LLC
KANSAS CITY, Mo., May 31, 2018 (GLOBE NEWSWIRE) -- CicloMed LLC, a biotechnology company developing novel treatments for bladder cancer, today announced the presentation of a scientific poster...
CicloMed Announces Presentation of Preclinical Evidence for its Bladder Cancer Agent at AACR 2018 Meeting
April 12, 2018 09:00 ET
|
CicloMed LLC
KANSAS CITY, Mo., April 12, 2018 (GLOBE NEWSWIRE) -- CicloMed LLC, a biotechnology company developing novel treatments for bladder cancer, today announced the presentation of preclinical evidence...
CicloMed Announces First Patient Dosed with Ciclopirox Prodrug in Phase I Trial in Patients with Advanced Solid Tumors
February 28, 2018 10:08 ET
|
CicloMed LLC
KANSAS CITY, Mo., Feb. 28, 2018 (GLOBE NEWSWIRE) -- CicloMed LLC, a biotechnology company developing novel treatments for bladder cancer, today announced that the first patient has been dosed in a...
CicloMed Announces FDA Clearance of IND Application for Ciclopirox Prodrug in the Treatment of Bladder Cancer
October 11, 2017 09:00 ET
|
CicloMed LLC
KANSAS CITY, Mo., Oct. 11, 2017 (GLOBE NEWSWIRE) -- CicloMed LLC announced today that its development candidate for non-muscle-invasive and muscle-invasive bladder cancer, Ciclopirox Prodrug, was...